tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PVLA Stock Latest News

Palvella Therapeutics initiated with a Buy at Truist
The FlyPalvella Therapeutics initiated with a Buy at Truist
5d ago
PVLA
Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes
PremiumThe Fly
Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes
26d ago
PVLA
Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential
PremiumRatings
Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential
1M ago
PVLA
Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
PremiumThe Fly
Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
1M ago
PVLA
Palvella Therapeutics granted sixth U.S. patent covering rapamycin
PremiumThe Fly
Palvella Therapeutics granted sixth U.S. patent covering rapamycin
1M ago
PVLA
Palvella Therapeutics Holds Annual Stockholders Meeting
PremiumCompany AnnouncementsPalvella Therapeutics Holds Annual Stockholders Meeting
1M ago
8K
PVLA
Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant
Premium
The Fly
Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant
2M ago
PVLA
Palvella Therapeutics Advances in Rare Skin Disease Therapies
Premium
Company Announcements
Palvella Therapeutics Advances in Rare Skin Disease Therapies
2M ago
PVLA
Palvella Therapeutics appoints Kline as Chief Commercial Officer
PremiumThe Fly
Palvella Therapeutics appoints Kline as Chief Commercial Officer
2M ago
PVLA
Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position
PremiumRatings
Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position
2M ago
PVLA
Palvella Therapeutics price target lowered to $52 from $53 at Canaccord
PremiumThe Fly
Palvella Therapeutics price target lowered to $52 from $53 at Canaccord
2M ago
PVLA
Promising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN Platform
PremiumRatings
Promising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN Platform
2M ago
PVLA
Palvella Therapeutics Reports Strong Q1 Financial Results
PremiumCompany AnnouncementsPalvella Therapeutics Reports Strong Q1 Financial Results
2M ago
8K
PVLA
Palvella Therapeutics reports Q1 EPS (74c), consensus ($1.32)
Premium
The Fly
Palvella Therapeutics reports Q1 EPS (74c), consensus ($1.32)
2M ago
PVLA
Palvella Therapeutics expects cash to fund operations into H2 of 2027
Premium
The Fly
Palvella Therapeutics expects cash to fund operations into H2 of 2027
2M ago
PVLA
Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
PremiumRatings
Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
3M ago
PVLA
Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
PremiumThe Fly
Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
3M ago
PVLA
Palvella Therapeutics announces data on QTORIN rapamycin
PremiumThe Fly
Palvella Therapeutics announces data on QTORIN rapamycin
4M ago
PVLA
Palvella Therapeutics initiated with a Buy at Chardan
PremiumThe Fly
Palvella Therapeutics initiated with a Buy at Chardan
4M ago
PVLA
Palvella Therapeutics price target raised to $53 from $39 at Canaccord
PremiumThe FlyPalvella Therapeutics price target raised to $53 from $39 at Canaccord
4M ago
PVLA
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
Premium
Ratings
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
4M ago
PVLA
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
Premium
Ratings
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
4M ago
PVLA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >